Vanessa Emslie, chief medical officer at Willbe, looks into the reasons that HRT could be failing your patients.
Perimenopause care reached a historic turning point following the landmark removal of “Black Box” warnings for oestrogen therapy at the end of last year. In the past few years, there has been a rapid change in adoption of hormone replacement therapy (HRT) as a safe, transformative therapy option for long-term female health. However, as clinical barriers shift, research is correctly analysed and prescription volumes increase, a new challenge has emerged: the revolving door of patient attrition.
Current data from both the US and UK reveal a concerning clinical reality: More than 40% of women will discontinue HRT within the first 12 months. These women aren’t just losing out on quality-of-life symptom relief; they are walking away from clinics and their doctors feeling frustrated and broken, convinced that HRT doesn’t work for them.
The truth is that neither the clinic, the doctor, nor the medicine is failing the patient, but rather that the one-size-fits-all approach is failing to account for their unique genetic blueprint. To solve this, insights from genomic testing can help clinics shift from trial-and-error to precision prescribing, helping suffering women reduce their symptom burden and regain potential lost vitality.
Genetic reasons
Understanding why a patient isn’t responding requires looking deeper than standard blood panels. There are three common biological bottlenecks revealed by genomic testing that have a significant impact on HRT response.
Protocols dictate that we prescribe based on standard starting doses, but for patients with genetically driven receptor hypersensitivity, this can feel like a shock to the system. If a patient has specific genetic markers for sensitivity, a standard dose of progesterone can actually trigger the very anxiety and sleep disruption it was meant to alleviate. Estrogen sensitivity may trigger unwanted weight gain and bloating. Precision dosing ensures you aren’t overloading a finely tuned system.
Some patients may appear non-responsive or flat-lined despite faithful adherence to their HRT. Their genetic profile may be programmed to clear hormones so rapidly that they never reach the cells effectively. These patients don’t need a fix, they need a recalibrated strategy that uses targeted nutrients to support key hormone variants, ensuring the HRT actually has time to work. They also may need help to support neurotransmitter function, which has a key role in supporting hormone response. Too often, the doses are simply increased.
HRT success is as much about the right dosage as it is about optimal detoxification. If a patient’s genetic profile indicates reduced efficiency in Phase I or Phase II detoxification (including variants like COMT or MTHFR), hormones can circulate too long. This leads to toxic build-up, resulting in common complaints like breast tenderness and weight gain rather than the improved vitality they were promised. This can also lead to genotoxic metabolites, so understanding the genes that guide optimal detoxification can help tailor supporting nutrigenomic strategies.
The sensitive archetype
Consider Sarah, a 48-year-old patient who had 18 months of failed HRT trials, despite being on standard transdermal oestrogen, she suffered from debilitating migraines and histamine flares.
A deep dive genetic analysis identified her as a hormone-sensitive archetype, with elevated histamine and oestrogen responses. Her system was amplifying her oestrogen HRT, turning what was considered a therapeutic dose into a trigger for histamine response. By reducing her oestrogen dose and adding targeted methylation support (methylated B vitamins and quercetin), her migraines stopped and her histamine response (skin, itching and also increased sensitivity to her normal diet) restored within weeks.
To help clinics streamline their decision-making, we have developed a genetic categorisation of patients into three distinct archetypes.
The first group are hormone responsive or typical responders with resilient feedback and detoxification loops. The second are hormone sensitive. These are highly reactive to hormones and require micro-titration alongside metabolic support. Finally, there are those we have categorised as hormone silent. These are rapid clearers who require receptor reawakening and clearance support.
By identifying these phenotypes early, clinics can reduce patient attrition, improve clinical outcomes, and offer a truly personalised care model that resonates in today’s data-driven health market.
